Aptinyx Revenue and Competitors

Claim your profile

Chicago, IL USA

Location

$268.3M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Aptinyx's estimated annual revenue is currently $1M per year.(i)
  • Aptinyx received $70.0M in venture funding in December 2017.
  • Aptinyx's estimated revenue per employee is $22,222
  • Aptinyx's total funding is $268.3M.
  • Aptinyx's current valuation is $198.4M. (January 2022)

Employee Data

  • Aptinyx has 45 Employees.(i)
  • Aptinyx grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$485.6M195816%$1.1BN/A
#2
$28.4M18337%N/AN/A
#3
$3.6M2353%N/AN/A
#4
$2.3M1515%N/AN/A
#5
$5.9M38-12%N/AN/A
#6
$5.4M353%N/AN/A
#7
$3.4M2210%N/AN/A
#8
$8.1M0N/A$122.3MN/A
#9
$2.5M1633%N/AN/A
#10
$1.2M15-25%$5.8MN/A

Welcome to our company page and thank you for your interest in Aptinyx Inc. Aptinyx is a biopharmaceutical company discovering and developing innovative therapies for challenging disorders of the brain and nervous system. Aptinyx has a proven platform for discovering proprietary compounds that work through a novel mechanism: modulation of the NMDA receptor to enhance pathways involved with nerve cell communication. Our goal is to rapidly advance our most promising drug candidates into clinical development for indications with high unmet medical need. At Aptinyx, we remain committed and responsive to our employees. We offer an engaging work environment, challenging work assignments, and competitive compensation and benefits. If you are interested in learning more, please visit our website at www.aptinyx.com.

keywords:N/A

$268.3M

Total Funding

45

Number of Employees

$1M

Revenue (est)

-2%

Employee Growth %

$198.4M

Valuation

N/A

Accelerator

Aptinyx News

2022-04-20 - Aptinyx (NASDAQ:APTX) Stock Rating Lowered by Zacks ...

According to Zacks, “Aptinyx Inc. is a bio-pharmaceutical company. It focuses on discovery, development, and commercialization of novel,...

2022-04-17 - Aptinyx Announces Publication in Molecular Psychiatry Demonstrating Reduction of Spontaneous Recovery of Fear ...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...

2022-04-17 - Aptinyx pauses phase 2 trial of higher dose PTSD med without explanation

Trouble continues for Aptinyx after it suddenly paused initiation of the higher dose arm of a phase 2b trial for a PTSD med.

2021-11-10 - Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights - Form 8-K

Aptinyx Reports Third Quarter 2021 Financial Results and Recent Highlights Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairme ...

2021-09-16 - Aptinyx : Secures $50 Million Growth Capital Credit Facility from K2 HealthVentures

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that it has entered into a $50 million loan facility and security agreement with K2 HealthVentures (K2HV). The fund ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$7.6M4510%N/A
#2
$7.6M46-15%N/A
#3
$5.8M4833%N/A
#4
$3.5M4914%N/A
#5
$6.6M4914%N/A

Aptinyx Funding

DateAmountRoundLead InvestorsReference
2016-05-10$65.0MANew Leaf Venture PartnersArticle
2017-12-19$70.0MBBain Capital Life SciencesArticle